Optune Lua is a wearable device for which tumor-treating fields (TTFields) inhibit the proliferation and metastasis of lung ...

Leerink Partners analyst Jonathan Chang maintained a Buy rating on NovoCure (NVCR – Research Report) yesterday and set a price target of ...

Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat ...

Novocure stock rocketed late Tuesday after the FDA signed off on its treatment for patients with metastatic lung cancer.

Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...

Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...

Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...

Novocure (NASDAQ:NVCR) shares rose 6% after market on announcing U.S. FDA approval for Optune Lua for the treatment of adult ...

The clinical practicums that are guaranteed from May-June during the first three years of study, and the opportunity to start working in the field of respiratory therapy after the third year of study ...

Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial markets open. Novocure management will host a conference ...

ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ ... development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved ...